[1]王志敏,金欢欢,卞勉励,等.lncRNA在慢性肝病中的作用与机制研究进展[J].中国药理学通报,2019,(08):1037-1040.[doi:10.3969/j.issn.1001-1978.2019.08.001]
 WANG Zhi-min,JIN Huan-huan,BIAN Mian-li,et al.Role and mechanism of lncRNA in chronic liver diseases[J].Chinese Pharmacological Bulletin,2019,(08):1037-1040.[doi:10.3969/j.issn.1001-1978.2019.08.001]
点击复制

lncRNA在慢性肝病中的作用与机制研究进展()
分享到:

《中国药理学通报》[ISSN:/CN:]

卷:
期数:
2019年08期
页码:
1037-1040
栏目:
讲座与综述
出版日期:
2019-08-14

文章信息/Info

Title:
Role and mechanism of lncRNA in chronic liver diseases
文章编号:
1001-1978(2019)08-1037-04
作者:
王志敏1金欢欢1卞勉励1开 钧1杨 祥1邵江娟23张 峰123郑仕中123
南京中医药大学1.江苏省中药药效与安全性评价重点实验室、 2.江苏省中药功效物质重点实验室、3.中药品质与效能国家重点实验室(培育),江苏 南京 210023
Author(s):
WANG Zhi-min1 JIN Huan-huan1 BIAN Mian-li1 KAI Jun1YANG Xiang1 SHAO Jiang-juan23 ZHANG Feng123 ZHENG Shi-zhong123
1.Jiangsu Provincial Key Lab of Efficacy and Safety Evaluation of Chinese Materia Medica; 2.Jiangsu Provincial Key Lab of Functional Materials for Chinese Materia Medica,3.State Key Lab of Quality and Efficacy of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing 210023,China
关键词:
长链非编码RNA 慢性肝炎 病毒性肝炎 酒精性脂肪肝 非酒精性脂肪肝 肝纤维化 肝癌
Keywords:
long non-coding RNA chronic hepatitis viral hepatitis alcoholic fatty liver nonalcoholic fatty liver liver fibrosis liver cancer
分类号:
R-05; R342.2; R575.1; R575.2; R575.5; R735.7
DOI:
10.3969/j.issn.1001-1978.2019.08.001
文献标志码:
A
摘要:
长链非编码RNA(long noncoding RNA,lncRNA)是一组长度>200 nt,且不具有编码蛋白功能的RNA转录本。在表观遗传、转录、转录后水平发挥生理功能。研究发现,lncRNA参与肝脏细胞多种生命过程,并已逐渐成为慢性肝病研究的热点,包括慢性肝炎、非酒精性脂肪肝、肝纤维化、肝癌等,尤其在肝癌方面。该文根据不同慢性肝病分类,详细阐述lncRNA与慢性肝病的密切关系,总结调控机制,预测lncRNA作用新靶点,为慢性肝病的研究和防治提供研究基础和新思路。
Abstract:
Long noncoding RNA(lncRNA)is a group of RNA transcripts with a length of>200 nt and does not function as an encoded protein.It functions at epigenetic, transcriptional, and post-transcriptional levels.lncRNA, involved in a variety of life processes in liver cells, has gradually become a hot topic in chronic liver diseases, including chronic hepatitis, non-alcoholic fatty liver, liver fibrosis, and liver cancer, etc, especially in liver cancer.This article elaborates the close relationship between lncRNA and chronic liver disease based on the classification of different chronic liver diseases, summarizes the regulatory mechanism to predict new targets of lncRNA, and provides research basis and new ideas for the study and prevention of chronic liver disease.

参考文献/References:

[1] Ulitsky I, Bartel D P.lincRNAs: genomics, evolution, and mechanisms[J].Cell, 2013, 154(1):26-46.
[2] Okazaki Y, Furuno M, Kasukawa T, et al.Analysis of the mouse transcriptome based on functional annotation of 60, 770 full-length cDNAs[J].Nature, 2002, 420(6915):563-73.
[3] Rinn J L, Kertesz M, Wang J K, et al.Functional demarcation of active and silent chromatin domains in human loci by noncoding RNAs[J].Cell, 2007, 129(7):1311-23.
[4] Wang K C, Chang H Y.Molecular mechanisms of long noncoding RNAs[J].Mol Cell, 2011, 43(6):904-14.
[5] 姜怀德, 李桂林.长非编码RNA的功能研究[J].中国药理学通报, 2015,31(7):900-5.
[5] Jiang H D, Li G L.Functional study of long non-coding RNA[J].Chin Pharmacol Bull, 2015,31(7):900-5.
[6] Zhao J, Fan Y, Wang K, et al.lncRNA HULC affects the differentiation of Treg in HBV-related liver cirrhosis[J].Int Immunospharmacol, 2015, 28(2):901-5.
[7] Zhang H, Xing Z, Mani S K, et al.RNA helicase DDX5 regulates PRC2/HOTAIR function in hepatitis B virus infection and hepatocarcinogenesis[J].Hepatology, 2016, 64(4):1033-48.
[8] Xia J, Xin L, Zhu W, et al.Characterization of long non-coding RNA transcriptome in high-energy diet induced nonalcoholic steatohepatitis minipigs[J].Sci Rep, 2016, 6:30709.
[9] Liu C, Yang Z, Wu J, et al.lncRNA H19 interacts with polypyrimidine tract-binding protein 1 to reprogram hepatic lipid homeostasis[J].Hepatology, 2017, 67(5):1768-83.
[10] Yan C, Chen J, Chen N.Long noncoding RNA MALAT1 promotes hepatic steatosis and insulin resistance by increasing nuclear SREBP-1c protein stability[J].Sci Rep, 2016, 6:22640.
[11] Li P, Ruan X B, Yang L, et al.A liver-enriched long non-coding RNA, lncLSTR, regulates systemic lipid metabolism in mice[J].Cell Metab, 2015, 21(3):455-67.
[12] 许文萱, 张自力, 赵士峰, 等.法尼酯衍生物X受体在慢性肝病中的作用及机制研究进展[J].中国药理学通报, 2016, 32(3):314-9.
[12] Xu W X, Zhang Z L, Zhao S F, et al.Advances in research on the role and mechanism of farnesoid derivative X receptor in chronic liver disease[J].Chin Pharmacol Bull, 2016, 32(3):314-9.
[13] Zhou C, York S R, Chen J Y, et al.Long noncoding RNAs expressed in human hepatic stellate cells form networks with extracellular matrix proteins[J].Genome Med, 2016, 8(1):31.
[14] He Y, Wu Y T, Huang C, et al.Inhibitory effects of long noncoding RNA MEG3 on hepatic stellate cells activation and liver fibrogenesis[J].Biochim Biophys Acta, 2014,1842(11):2204-15.
[15] Leti F, Legender C, Still C D, et al.Altered expression of MALAT1 lncRNA in nonalcoholic steatohepatitis fibrosis regulates CXCL5 in hepatic stellate cells[J].Transl Res, 2017, 190:25-39.
[16] Zhang K, Han X H, Zhang Z, et al.The liver-enriched lnc-LFAR1 promotes liver fibrosis by activating TGF-β and Notch pathways[J].Nat Commun, 2017, 8(1):144.
[17] Song Y F, Liu C, Liu X, et al.H19 promotes cholestatic liver fibrosis by preventing ZEB1-mediated inhibition of EpCAM[J].Hepatology, 2017, 66(4):1183-96.
[18] Yuan S X, Wang J, Yang F, et al.Long noncoding RNA DANCR increases stemness features of hepatocellular carcinoma by derepression of CTNNB1[J].Hepatology, 2016, 63(2):499-511.
[19] Zhu P P, Wang Y Y, Huang G L, et al.lnc-beta-Catm elicits EZH2-dependent β-catenin stabilization and sustains liver CSC self-renewal[J].Nat Struct Mol Biol, 2016, 23(7):631-9.
[20] 王 雪.长链非编码RNA对肝癌干细胞的调控作用及分子机制[D].上海: 第二军医大学, 2016.
[20] Wang X.Long non-coding RNA regulates hepatocellular carcinoma stem cells and its molecular mechanism[D].Shanghai:the Second Military Medical University, 2016.
[21] Hua L, Wang C Y, Yao K H, et al.High expression of long non-coding RNA ANRIL is associated with poor prognosis in hepatocellular carcinoma[J].Int J Exp Pathol, 2015, 8(3):3076-82.
[22] Ma J, Li T F, Han X W, et al.Knockdown of lncRNA ANRIL suppresses cell proliferation, metastasis, and invasion via regulating miR-122-5p expression in hepatocellular carcinoma[J].J Cancer Res Clin, 2018,144(2):205-14.
[23] Li D, Liu X F, Zhou J, et al.lncRNA HULC modulates the phosphorylation of YB-1 through serving as a scaffold of ERK and YB-1 to enhance hepatocarcinogenesis[J].Hepatology, 2016, 65(5):1612-27.
[24] Chen R P, Huang Z L, Liu L X, et al.Involvement of endoplasmic reticulum stress and p53 in lncRNA MEG3-induced human hepatoma HepG2 cell apoptosis[J].Oncol Rep, 2016, 36(3):1649-57.
[25] Xiong H, Ni Z, He J, et al.lncRNA HULC triggers autophagy via stabilizing Sirt1 and attenuates the chemosensitivity of HCC cells[J].Oncogene, 2017, 36(25):3528-40.

相似文献/References:

[1]彭 艳,谢海棠,孙 红,等.人长链非编码RNA基因H19克隆、表达载体构建及对MCF-7细胞增殖的影响[J].中国药理学通报,2015,(04):555.
 PENG Yan,XIE Hai-tang,SUN Hong,et al.Constructing an expression vector for human lncRNA H19 and the effect of its overexpression on MCF-7 cell proliferation[J].Chinese Pharmacological Bulletin,2015,(08):555.
[2]董宪喆,胡 园,刘 屏,等.lncRNA作为竞争性内源RNA调控胃癌进程的研究进展[J].中国药理学通报,2016,(09):1185.[doi:10.3969/j.issn.1001-1978.2016.09.001]
 DONG Xian-zhe,HU Yuan,LIU Ping,et al.The research progress of lncRNA as CeRNA in gastric cancer[J].Chinese Pharmacological Bulletin,2016,(08):1185.[doi:10.3969/j.issn.1001-1978.2016.09.001]
[3]高梦如,魏小丽,顾康生.长链非编码RNA在肿瘤耐药中的作用[J].中国药理学通报,2017,(12):1641.[doi:10.3969/j.issn.1001-1978.2017.12.004]
 GAO Meng-ru,WEI Xiao-li,GU Kang-sheng.Role of long non-coding RNA in drug resistance of tumor[J].Chinese Pharmacological Bulletin,2017,(08):1641.[doi:10.3969/j.issn.1001-1978.2017.12.004]
[4]戴凯琴,刘 俊,凌 霜,等.LncRNAs在细胞衰老中的作用和治疗靶标[J].中国药理学通报,2019,(04):464.[doi:10.3969/j.issn.1001-1978.2019.04.004]
 DAI Kai-qin,LIU Jun,LING Shuang,et al.Role of LncRNAs in cell senescence and therapeutic targets[J].Chinese Pharmacological Bulletin,2019,(08):464.[doi:10.3969/j.issn.1001-1978.2019.04.004]

备注/Memo

备注/Memo:
收稿日期:2019-04-03,修回日期:2019-05-05
基金项目:国家自然科学基金项目(No 8127054,31571455,31401210,31600653,81600483); 江苏省自然科学基金项目(No BK 20140955); 江苏高校优势学科建设工程资助项目(PAPD)
作者简介:王志敏(1995-),女,硕士生,研究方向:天然药物预防和治疗肿瘤及肝纤维化,E-mail:1187564859@qq.com;
郑仕中(1962-),男,博士,教授,博士生导师,研究方向:天然药物预防和治疗肿瘤及肝纤维化,通讯作者,Tel:025-85811246,E-mail:nytws@163.com
更新日期/Last Update: 2019-08-14